Stryker reports Q4 2025 sales $7.2B, +11% organic; 2026 outlook 8-9.5% organic growth

STRYKER CORP

2025-FY EPS reported $8.40 revenue$25,116,000,000

Q4 reported EPS $2.20 (+56% YoY); adjusted EPS $4.47 (+11.5%).
Full year net sales $25.1B (+11.2% reported); organic growth 10.3%.
MedSurg & Neurotechnology Q4 organic sales +12.6%; Orthopaedics +8.4% organic.
Adjusted operating margin expanded 100 bps to 30.2% in Q4, 26.3% full year.
2026 guidance: organic sales growth 8.0%-9.5%; adjusted EPS $14.90-$15.10.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.